Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 803678, 3 pages
http://dx.doi.org/10.1100/2012/803678
Research Article

Intra-Arterial Prostaglandin E1 Infusion in Patients with Rest Pain: Short-Term Results

1Department of Interventional Radiology, Aretaieion Hospital, University of Athens, 76 Vas. Sofias Avenue, 115 28 Athens, Greece
2Department of Radiology, Aretaieion Hospital, 76 Vas. Sofias, 115 28 Athens, Greece
3Department of Vascular Surgery, Aretaieion Hospital, Aretaieion Hospital, 76 Vas. Sofias Avenue, 115 28 Athens, Greece

Received 25 October 2011; Accepted 17 November 2011

Academic Editor: Takuji Yamagami

Copyright © 2012 A. Chatziioannou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Balzer, W. Rogatti, and K. Tuttgerodt, “Efficacy and tolerability of intraarterial and inravenous PGE, infusions in occlusive arterial disease stage III/IV,” Vasa, vol. 28, supplement, pp. 31–38, 1989. View at Google Scholar
  2. E. P. Strecker, I. Boos, W. Ostheim-Dzerowycz, R. Heber, and S. Vetter, “Percutaneously implantable catheter-port system: preliminary tehcnical results,” Radiology, vol. 202, pp. 574–577, 1997. View at Google Scholar
  3. E. P. Strecker, W. Ostheim-Dzerowycz, and I. Boos, “Intraarterial infusion therapy via a subcutaneous port for limb-threatening ischemia: a pilot study,” CardioVascular and Interventional Radiology, vol. 21, pp. 109–115, 1998. View at Google Scholar
  4. T. Brecht and M. Ayaz, “Circulation parameters during intravenous and intraarterial administration of increasing doses of postaglandine E1 in healthy subjects,” Klin Wochenschr, vol. 63, pp. 1201–1209, 1985. View at Google Scholar
  5. J. D. Gruss, H. Vargas-Montano, D. Bartels et al., “Use of prostaglandins in arterial occlusive disease,” Inter Angio, vol. 3, supplement, pp. 7–17, 1984. View at Google Scholar
  6. M. T. De Sanctis, L. Incandela, and P. Iacobitti, “'Responders and non-responders' to PGE1 and alpha-cyclodextrin,” Minerva Cardioangiologica, vol. 10, supplement, pp. 31–36, 1998 (Italian). View at Google Scholar
  7. G. Laurora, M. Corsi, M. Bucci, M. R. Cesarone, G. Belcaro, and M. Dugall, “European trial of PGE1 alpha cyclodextrin: short-term versus long-term therapy in intermittent claudication,” Minerva Cardioangiologica, vol. 10, supplement, pp. 21–29, 1998 (Italian). View at Google Scholar
  8. H. W. Krawzak, H. Strosche, J. Buchholz, and F. Jakel, “Implantation technique and complications of totally implanted arterial access systems for long-term therapy in patients with occlusive vascular disease,” Cardiovascular Surgery, vol. 30, no. 6, pp. 921–924, 1998 (Italian). View at Google Scholar
  9. G. Laurora, G. Belcaro, M. R. Cesarone, L. Incandela, M. T. De Sanctis, and M. Dugall, “Global analysis of data from studies with PDE1 alpha-cyslodextrin,” Minerva Cardioangiologica, vol. 10 supplement, pp. 65–68, 1998 (Italian). View at Google Scholar
  10. G. Limouris, A. Hatziioannou, V. Voliotopoulos, D. Mourikis, A. Frantzis, and L. Vlachos, “Selective intraarterial prostaglandin PGE1 infusion via subcutaneous port for limb threatening ischemia,” in Proceedings of the Abstract RSNA Scientific Meeting, pp. 25–30, Chicago, Ill, USA, 2001.
  11. G. Belcaro and M. R. Caserone, “Increasing transcutanoues PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin,” Minerva Cardioangiologica, vol. 10, supplement, pp. 37–43, 1998 (Italian). View at Google Scholar
  12. M. Bucci, P. Iacobitti, G. Laurora, and M. R. Cesarone, “Analysis of costs and results of prostaglandin (PGE1 alpha-cystodestrin) therapy of peripheral arterial diseases,” Minerva Cardioangiologica, vol. 10, supplement, pp. 9–15, 1998 (Italian). View at Google Scholar